inadequate response
Showing 1 - 25 of >10,000
Rheumatoid Arthritis Trial in Beijing (TLL-018, Tofacitinib)
Not yet recruiting
- Rheumatoid Arthritis
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Aug 25, 2023
Prospective, Multi-Center, Observational, Whole Blood Specimen
Not yet recruiting
- Rheumatoid Arthritis
- (no location specified)
Jun 30, 2023
Essential Thrombocythemia Trial (Bomedemstat, Anagrelide, Busulfan)
Not yet recruiting
- Essential Thrombocythemia
- Bomedemstat
- +4 more
- (no location specified)
Oct 6, 2023
Major Depressive Disorder With Anhedonia and Inadequate Response
Not yet recruiting
- Depressive Disorder, Major
- No Intervention
- (no location specified)
Apr 24, 2023
Rheumatoid Arthritis Trial in Chi?inau (AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg)
Recruiting
- Rheumatoid Arthritis
- AP1189, 60 mg
- +3 more
-
Chișinău, Moldova, Republic ofTimofei Mosneaga Republican Clinical Hospital
Jan 5, 2023
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- BCX9930
- +2 more
-
Paris, France
- +6 more
Dec 15, 2022
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Italy, United Kingdom, United States (Danicopan, Eculizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
Baltimore, Maryland
- +4 more
Aug 15, 2022
Hand Eczema Trial in Groningen (Dupilumab, Placebo)
Active, not recruiting
- Hand Eczema
- Dupilumab
- Placebo
-
Groningen, NetherlandsUniversity Medical Center Groningen
Aug 18, 2022
COVID-19, SARS-CoV-2 Trial in Moscow, St Petersburg (Biological: AZD3152, Biological: Placebo)
Not yet recruiting
- COVID-19, SARS-CoV-2
- Biological: AZD3152
- Biological: Placebo
-
Moscow, Russian Federation
- +5 more
Sep 26, 2023
Major Depressive Disorder Who Have HadInadequate Response
Terminated
- Depressive Disorder, Major
- Standard of Care (SOC)
-
San Francisco, California
- +3 more
Dec 6, 2022
Primary Biliary Cholangitis Trial in Xi'an (Fenofibrate 200mg, Placebo, UDCA)
Recruiting
- Primary Biliary Cholangitis
- Fenofibrate 200mg
- +2 more
-
Xi'an, Shaanxi, ChinaXijing Hospital
Mar 3, 2023
Rheumatoid Arthritis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, )
Completed
- Rheumatoid Arthritis
- LNK01001 Dose A
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
Oct 24, 2023
Moderate-to-severe Atopic Dermatitis Trial (Nemolizumab, CD14152 )
Withdrawn
- Moderate-to-severe Atopic Dermatitis
- Nemolizumab
- CD14152 placebo
- (no location specified)
Jan 6, 2022
Primary Biliary Cholangitis Trial in Xi'an (Placebo Combined With Ursodeoxycholic Acid, Fenofibrate Combined With
Recruiting
- Primary Biliary Cholangitis
- Placebo Combined With Ursodeoxycholic Acid
- Fenofibrate Combined With Ursodeoxycholic Acid
-
Xi'an, Shaanxi, ChinaYing han
Mar 3, 2023
Rheumatoid Arthritis Trial in Beijing (BAT1806, Actemra(EU-licensed))
Completed
- Rheumatoid Arthritis
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Nov 16, 2021
Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Trial in Paris (Rituximab,
Not yet recruiting
- Granulomatosis With Polyangiitis
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Rituximab
- +2 more
-
Paris, FranceHôpital de la Croix Saint Simon
Oct 10, 2022
How Often Psychiatric Conditions Who Did Not Respond To
Not yet recruiting
- Attention Deficit Hyperactivity Disorder (ADHD)
- (no location specified)
Aug 22, 2022
Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab
Recruiting
- Rheumatoid Arthritis
- +4 more
- filgotinib 200mg/day
- subcutaneous tocilizumab 162mg/biweekly
-
Nagasaki, JapanNagasaki University Hospital
Oct 23, 2021
Migraine Trial in United States (AXS-07 (meloxicam-rizatriptan))
Recruiting
- Migraine
- AXS-07 (meloxicam-rizatriptan)
-
Colton, California
- +18 more
Sep 19, 2022